November 25, 2025 — Carlsbad, CA — Leads & Copy —
Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on advancing next-generation, once-daily, oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases, has announced that its Chief Executive Officer, JD Finley, and Chief Medical Officer, Dr. Mitchell Jones, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:30 AM ET.
In addition to the fireside chat, Palisade Bio’s management will be available for one-on-one in-person meetings with qualified members of the investor community registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the company’s website (palisadebio.com). The webcast replay will be available two hours after the live event and archived for 90 days.
Palisade Bio is committed to transforming proven PDE4 biology into safer oral therapies for patients with chronic inflammatory and fibrotic diseases through its differentiated prodrug platform and precision pharmacology strategy.
The company’s lead program, PALI-2108, is a locally bioactivated PDE4 inhibitor prodrug in development for moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn’s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options. A recently reported Phase 1b trial showed PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability, and pharmacokinetics consistent with sustained localized activation, low systemic exposure, and controlled release within the GI tract.
Palisade Bio is moving forward with a Phase 2 clinical study in UC to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, including an extension phase to assess maintenance of remission. The company is also preparing to initiate studies in FSCD to characterize PALI-2108’s safety, pharmacology, and therapeutic benefit across inflammatory bowel disease indications.
Investor Relations Contact:
Jenene Thomas
JTC Team, LLC
908-824-0775
PALI@jtcir.com
Source: Palisade Bio
